RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aclaris Therapeutics Stock

Aclaris Therapeutics Revenue 2024

Aclaris Therapeutics Revenue

14.49 M USD

Ticker

ACRS

ISIN

US00461U1051

WKN

A1412H

In 2024, Aclaris Therapeutics's sales reached 14.49 M USD, a -53.64% difference from the 31.25 M USD sales recorded in the previous year.

The Aclaris Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e51.1725,73
2028e32.6440,34
2027e14.8388,79
2026e7.69171,24
2025e9.23142,67
2024e14.4990,89
202331.2542,14
202229.7559,80
20216.7630,33
20206.4820,83
20194.234,02
20186.1529,59
20171.6828,57
2016--
2015--
2014--
2013--

Aclaris Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aclaris Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aclaris Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aclaris Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aclaris Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aclaris Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aclaris Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aclaris Therapeutics’s growth potential.

Aclaris Therapeutics Revenue, EBIT and net profit per share

DateAclaris Therapeutics RevenueAclaris Therapeutics EBITAclaris Therapeutics Net Income
2029e51.17 M undefined0 undefined-2.55 M undefined
2028e32.64 M undefined-42.34 M undefined-10.92 M undefined
2027e14.83 M undefined-58.88 M undefined-22.19 M undefined
2026e7.69 M undefined-60.03 M undefined-52.83 M undefined
2025e9.23 M undefined-55.24 M undefined-46.88 M undefined
2024e14.49 M undefined-62.13 M undefined-43.17 M undefined
202331.25 M undefined-89.41 M undefined-88.48 M undefined
202229.75 M undefined-85.15 M undefined-86.91 M undefined
20216.76 M undefined-65.38 M undefined-90.87 M undefined
20206.48 M undefined-50.91 M undefined-51.02 M undefined
20194.23 M undefined-92.56 M undefined-161.35 M undefined
20186.15 M undefined-84.78 M undefined-132.74 M undefined
20171.68 M undefined-72.42 M undefined-68.52 M undefined
20160 undefined-48.57 M undefined-48.08 M undefined
20150 undefined-20.67 M undefined-23.13 M undefined
20140 undefined-8.53 M undefined-10.57 M undefined
20130 undefined-5.26 M undefined-6.98 M undefined

Aclaris Therapeutics stock margins

The Aclaris Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aclaris Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aclaris Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aclaris Therapeutics's sales revenue. A higher gross margin percentage indicates that the Aclaris Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aclaris Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aclaris Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aclaris Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aclaris Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aclaris Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aclaris Therapeutics Margin History

Aclaris Therapeutics Gross marginAclaris Therapeutics Profit marginAclaris Therapeutics EBIT marginAclaris Therapeutics Profit margin
2029e42.14 %0 %-4.98 %
2028e42.14 %-129.72 %-33.44 %
2027e42.14 %-397.01 %-149.65 %
2026e42.14 %-780.66 %-686.98 %
2025e42.14 %-598.49 %-507.94 %
2024e42.14 %-428.82 %-298 %
202342.14 %-286.13 %-283.15 %
202259.8 %-286.22 %-292.13 %
202130.33 %-967.16 %-1,344.23 %
202020.83 %-785.65 %-787.35 %
20194.02 %-2,188.18 %-3,814.42 %
201829.59 %-1,378.54 %-2,158.37 %
201728.57 %-4,310.71 %-4,078.57 %
201642.14 %0 %0 %
201542.14 %0 %0 %
201442.14 %0 %0 %
201342.14 %0 %0 %

Aclaris Therapeutics Aktienanalyse

What does Aclaris Therapeutics do?

Aclaris Therapeutics Inc was founded in 2012 and is based in Wayne, Pennsylvania. The company focuses on the development and marketing of innovative solutions for the treatment of skin problems and other diseases that significantly impact the quality of life of those affected. Aclaris' business model is based on the research and development of new therapies that address various medical problems and conditions. The company employs a combination of internal research projects and the acquisition of promising products and pipeline assets from third-party companies. Aclaris is divided into different business segments that focus on various medical issues and conditions. One important area is dermatology, where the company has developed several innovative products and therapies. This includes RHOFADE® (Oxymetazoline Hydrochloride), a topical medication for the treatment of rosacea. The novel product A-101, used for the treatment of seborrheic keratosis, has also been established in the market. In the field of oncological dermatology, Aclaris has a promising pipeline focused on the development of drugs for the treatment of actinic keratosis, basal cell carcinoma, squamous cell carcinoma, and melanoma. The company collaborates closely with scientists and research institutions to develop innovative solutions that can revolutionize the pharmaceutical market. Another area that Aclaris focuses on is immunology, including the development of new therapies for the treatment of inflammatory diseases such as alopecia areata, an autoimmune disease that causes hair loss. Aclaris has already made significant progress in this area and is conducting clinical studies to demonstrate the effectiveness of its products in treating this condition. In addition to the development of innovative therapies, Aclaris also collaborates closely with other companies and research institutions to develop platform technologies that can accelerate and simplify the development of new drugs. This includes state-of-the-art analytical methods and the development of new molecules that specifically target certain diseases. Aclaris' business model has proven successful in recent years. The company combines internal research projects with the acquisition of promising pipeline assets from third-party companies to expand its portfolio and pipeline. This approach allows Aclaris to quickly respond to changing market conditions and patient needs, positioning themselves as a leading player in the pharmaceutical market. Aclaris' products have already improved many lives and successfully treated numerous patients with various medical problems. The company aims to achieve sustainable improvement in the quality of life of patients and continuously develop new innovative solutions to secure a leading position in the highly competitive pharmaceutical market. Aclaris Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Aclaris Therapeutics's Sales Figures

The sales figures of Aclaris Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Aclaris Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Aclaris Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Aclaris Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Aclaris Therapeutics stock

How much revenue did Aclaris Therapeutics generate this year?

Aclaris Therapeutics has achieved a revenue of 14.49 M USD this year.

How much was the turnover of the company Aclaris Therapeutics compared to the previous year?

The revenue of Aclaris Therapeutics has increased by -53.64% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Aclaris Therapeutics?

The revenue of Aclaris Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Aclaris Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Aclaris Therapeutics so important for investors?

The revenue of Aclaris Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Aclaris Therapeutics pay?

Over the past 12 months, Aclaris Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aclaris Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aclaris Therapeutics?

The current dividend yield of Aclaris Therapeutics is .

When does Aclaris Therapeutics pay dividends?

Aclaris Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aclaris Therapeutics?

Aclaris Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aclaris Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aclaris Therapeutics located?

Aclaris Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aclaris Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aclaris Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Aclaris Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Aclaris Therapeutics in the year 2023?

In the year 2023, Aclaris Therapeutics distributed 0 USD as dividends.

In which currency does Aclaris Therapeutics pay out the dividend?

The dividends of Aclaris Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aclaris Therapeutics

Our stock analysis for Aclaris Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aclaris Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.